<div id="readability-page-1"><p>Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Apogee Therapeutics today and set a price target of $130.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Travere Therapeutics, and Kiniksa Pharmaceuticals. According to TipRanks, Nash has an average return of <span>25.7%</span> and a 50.48% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apogee Therapeutics with a $122.25 average price target.</p></div>

APGE

SBIO

LABU

<p>Canaccord Genuity analyst Edward Nash has maintained a Buy rating for Apogee Therapeutics (APGE) with a price target of $130.00. The analyst has an average return of 25.7% and a 50.48% success rate on his stock recommendations. The overall analyst consensus for Apogee Therapeutics is a Strong Buy, with an average price target of $122.25.</p>

Tip Ranks

Apogee Therapeutic

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Corcept Therap

Travere Therapeutics

Kiniksa Pharmaceuticals

Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)